Business
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physician Education Lead, and to its Scientific Advisory Board (SAB), effective January 2026.Dr. Alper will work with Hemostemix on a focused set of physician-led education and clinical engagement initiatives, engaging with wound-care podiatrists, and multidisciplinary limb-preservation teams, starting in Florida.Dr. Alper will assist Hemostemix in executing three parallel initiatives:Clinical Practice Engagement in FloridaDr. Alper will engage with wound-care podiatry practitioners and multidisciplinary limb salvage teams in Florida, to detail how VesCell (ACP-01) addresses pain and the ischemia-root-cause of peripheral arterial disease, diabetic foot ulcers, and amputation. This effort is designed to support increased use of ACP-01 in each medical practice, following responsible clinical education and data-informed practice development. Schools of Podiatric MedicineDr. Alper will engage Deans of Clinical Education at U.S. schools of podiatry medicine. This initiative will introduce graduating doctors of podiatry, and faculty, on ACP-01 intervention.Multidisciplinary Education & Professional ForumsDr. Alper will support Hemostemix's participation in multidisciplinary educational forums involving podiatrists, vascular specialists, interventional physicians, nurses, and wound-care professionals. Content will focus on ischemic disease phenotyping, patient selection, procedural considerations, and ACP-01's integration into real-world team-based practices.About Dr. David B. AlperDr. Alper is a nationally recognized podiatry physician and leader in wound care, limb preservation, and diabetic foot management. He currently serves as a Trustee of the American Podiatric Medical Association, is a Fellow of the Royal College of Physicians and Sur...